- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01223079
Use of r-hLH (Luveris) in Donors Previously Treated With r-hFSH (Gonal F)
Use of r-hLH (Luveris) Late Follicular Phase for Controlled Ovarian Stimulation (COS) in Donor Patients Previously Treated With r-hFSH (Gonal F)in a Long Luteal Downregulated Cycle With GnRH Agonist. A Cross-over Study
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
While the role of FSH is considered the fundamental driver of folliculogenesis, the role of LH in this process is more controversial. FSH is associated with stimulating growth and recruitment of follicles while LH is associated with the selection of dominant follicles destined for ovulation. We will use an open, prospective, cross-over study to compare the safety and efficacy of two different treatment protocols for controlled ovarian stimulation in egg donors.
20 participants will undergo two cycles of stimulation. The first one will be with r-hFSH though the cycle and the second with r-hFSH then r-hLH. The participants will have 1 month rest cycle between the treatment cycles. r-hFSH doses will be adjusted according to patient response. r-hLH dosing will begin when there are 2 follicles greater than or equal to 14mm in diameter. The does will be 300IU/day and continue until the day of r-hCG administration.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New Jersey
-
Morristown, New Jersey, Forente stater, 07960
- Reproductive Medicine Assoicates of New Jersey
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Age less than or equal to 32 years old
- BMI<35
- Eligible for controlled ovarian simulation
- No PCO-type ovaries (PCO by USS image, >2.1 LH;FSH ratio on cycle day 3, insulin resistance, increase of testosterone over free testosterone)
- Meet all requirements for becoming an egg donor
- Willingness and ability to participate and comply with study protocol for the duration of the study
- Baseline FSH<11
Exclusion Criteria:
- Clinically significant systemic disease
- Any contraindication to gonadotropin therapy
- LH:FSH ratio greater than 3
- Pregnancy in the past 3 months
- Any medical condition which, in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug
- Simultaneous participation in another clinical trial
- Known active substance abuse, including tobacco and alcohol (>10 cigarettes/day)
- Refusal or inability to comply with protocol
- Known poor ovarian response
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Annen: r-hFSH (Gonal F)
Patients will be treated with r-hFSH throughout the stimulation phase of their first cycle until r-hCG administration.
|
r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
Andre navn:
|
Annen: r-hFSH (Gonal F) and r-hLH (Luveris)
Patients will be treated with r-hFSH only until they have 2 follicles greater than or equal to 14mm.
Patients will then bring 300IU/day of r-hLH until r-hCG administration.
|
Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Safety and efficacy of r-hFSH protocol
Tidsramme: 6 months
|
Evaluation of the safety and efficacy of r-hFSH for controlled ovarian stimulation in the same patients.
|
6 months
|
Safety and efficacy of r-hFSH + r-hLH protocol
Tidsramme: 6 months
|
Evaluation of the safety and efficacy of r-hFSH for controlled ovarian stimulation in the same patients.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of oocytes retrieved
Tidsramme: 6 months
|
Evaluation of the number of oocytes obtained as a function of stimulation protocol.
|
6 months
|
Quality of embryos obtained
Tidsramme: 6 months
|
Evaluation of pregnancy rates (clinical and ongoing), delivery rates, multiple pregnancy rates and the number of cancelled cycles.
|
6 months
|
Incidences of ovarian hyperstimulation syndrome
Tidsramme: 6 months
|
Evaluation of the potential adverse effects associated with ovarian stimulation
|
6 months
|
Quality of oocytes obtained
Tidsramme: 6 months
|
Evaluation of the quality of oocytes obtained as a function of stimulation protocol.
|
6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Richard T Scott, MD, Reproductive Medicine Associates of New Jersey
Publikasjoner og nyttige lenker
Hjelpsomme linker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20052361
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på r-hFSH
-
Finox AGFullført
-
Finox AGFullførtInfertilitetTyskland
-
Merck KGaA, Darmstadt, GermanyFullført
-
Merck KGaA, Darmstadt, GermanyMerck Serono S.P.A., ItalyAvsluttetReproduktive teknikker, assistertItalia
-
Medical University of ViennaSuspendert
-
Merck KGaA, Darmstadt, GermanyMerck Pte. Ltd., SingaporeFullført
-
Merck KGaA, Darmstadt, GermanyFullført
-
Merck KGaA, Darmstadt, GermanyMerck, S.L., SpainAvsluttetInfertilitet | Induksjon av eggløsningSpania
-
Merck KGaA, Darmstadt, GermanyFullført
-
Centro Riproduzione e AndrologiaFullførtHypogonadotropisk hypogonadismeItalia